Literature DB >> 30939060

Description of Continuous Palliative Sedation Practices in a Large Health Region and Comparison with Clinical Practice Guidelines.

Amane Abdul-Razzak1, Laurie Lemieux1, Maggie Snyman2, Grace Perez3, Aynharan Sinnarajah1,3,4.   

Abstract

Background: Published reports of continuous palliative sedation therapy (CPST) suggest heterogeneity in practice. There is a paucity of reports that compare practice with clinical guidelines.
Objectives: To assess adherence of continuous palliative sedation practices with criteria set forth in local clinical guidelines, and to describe other features including prevalence, medication dosing, duration, multidisciplinary team involvement, and concurrent therapies. Design: Retrospective chart review. Settings/Subjects: We included cases in which a midazolam infusion was ordered at the end of life. Study sites included four adult hospitals in the Calgary health region, two hospices, and a tertiary palliative care unit. Measurements: Descriptive data, including proportion of deaths involving palliative sedation therapy, number of criteria documented, midazolam dose/duration, concurrent symptom management therapies, and referrals to spiritual care, psychology, or social work.
Results: CPST occurred in 602 out of 14,360 deaths (4.2%). Full adherence to criteria occurred in 7% of cases. The most commonly missed criteria were: a "C2" goals-of-care designation order (comfort care focus in the imminently dying) (84%) and documentation of imminent death in the chart (55%). Concurrent medical therapies included opioids in 98% of cases and intravenous hydration in 85% of cases. Few referrals were made to multidisciplinary care teams. Conclusions: We found low adherence to palliative sedation guidelines. This may reflect the perception that some criteria are redundant or clinically unimportant. Future work could include a study of barriers to guideline uptake, and guideline modification to provide direction on concurrent therapies and multidisciplinary team involvement.

Entities:  

Keywords:  acute care; continuous palliative sedation therapy; hospice; midazolam; practice guidelines; terminal sedation

Year:  2019        PMID: 30939060     DOI: 10.1089/jpm.2018.0372

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  5 in total

1.  Sedatives and Sedation at the End of Life in the Hospital.

Authors:  Eva Schildmann; Sophie Meesters; Claudia Bausewein
Journal:  Dtsch Arztebl Int       Date:  2022-05-27       Impact factor: 8.251

Review 2.  How to measure the effects and potential adverse events of palliative sedation? An integrative review.

Authors:  Alazne Belar; María Arantzamendi; Sheila Payne; Nancy Preston; Maaike Rijpstra; Jeroen Hasselaar; Lukas Radbruch; Michael Vanderelst; Julie Ling; Carlos Centeno
Journal:  Palliat Med       Date:  2020-12-14       Impact factor: 4.762

3.  Inappropriate use of clinical practices in Canada: a systematic review.

Authors:  Janet E Squires; Danielle Cho-Young; Laura D Aloisio; Robert Bell; Stephen Bornstein; Susan E Brien; Simon Decary; Melissa Demery Varin; Mark Dobrow; Carole A Estabrooks; Ian D Graham; Megan Greenough; Doris Grinspun; Michael Hillmer; Tanya Horsley; Jiale Hu; Alan Katz; Christina Krause; John Lavis; Wendy Levinson; Adrian Levy; Michelina Mancuso; Steve Morgan; Letitia Nadalin-Penno; Andrew Neuner; Tamara Rader; Wilmer J Santos; Gary Teare; Joshua Tepper; Amanda Vandyk; Michael Wilson; Jeremy M Grimshaw
Journal:  CMAJ       Date:  2022-02-28       Impact factor: 16.859

4.  Association between continuous deep sedation and survival time in terminally ill cancer patients.

Authors:  So-Jung Park; Hee Kyung Ahn; Hong Yup Ahn; Kyu-Tae Han; In Cheol Hwang
Journal:  Support Care Cancer       Date:  2020-05-15       Impact factor: 3.603

5.  Impact of legalization of Medical Assistance in Dying on the Use of Palliative Sedation in a Tertiary Care Hospital: A Retrospective Chart Review.

Authors:  Amy Nolen; Rawaa Olwi; Selby Debbie
Journal:  Am J Hosp Palliat Care       Date:  2021-07-06       Impact factor: 2.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.